Ovid Therapeutics Inc. 8-K

What Happened
On May 12, 2026, Ovid Therapeutics, Inc. announced business updates and reported its first quarter 2026 financial results in a press release that was furnished with the SEC on Form 8-K (Exhibit 99.1). The current report was signed by Jeffrey Rona, Chief Business and Financial Officer.

Key Details

• Filing date: May 12, 2026.
• Press release announcing business updates and Q1 2026 financial results furnished as Exhibit 99.1 to the Form 8-K.
• Cover page interactive XBRL data included (Exhibit 104).
• Form 8-K signed by Jeffrey Rona, Chief Business and Financial Officer.

Why It Matters
This 8-K points investors to Ovid’s latest quarterly results and operational updates — key information for assessing recent earnings, revenue trends, cash position and progress on the company’s programs. Retail investors should read the furnished press release (Exhibit 99.1) for the specific financial figures and business developments disclosed on May 12, 2026.